Notably, the reported efficacy of Everolimus (an mTOR-targeted inhibitor) in combination with letrozole (an aromatase inhibitor) for recurrent endometrial cancers (31, 32)underscores the potential for enhanced antitumor efficacy through the identification of suitable candidates for treatment with mTOR inhibitors or other targeted agents in conjunction with hormonal agents. The gene discussed is CYP19A1; the disease is endometrial cancer.